BEVERLY, Mass., Oct. 31, 2017 (GLOBE NEWSWIRE) --
Post# of 72440
(Total Views: 265)
Posted On: 10/31/2017 11:06:39 AM
BEVERLY, Mass., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals
Inc. (OTCQB:IPIX) ( the Company ), a clinical stage biopharmaceutical company,
is pleased to report continued developments in its dermatology franchise.
The Company s randomized, placebo-controlled Phase 2b clinical trial of Prurisol
for chronic, moderate-to-severe plaque psoriasis (see NCT02949388), enrolling a
total of 199 patients, remains on-track for completion in December. Separately,
building upon promising results seen to date demonstrating its
anti-inflammatory, anti-infective and immunomodulatory properties, the Company
is looking to expand Brilacidin into treating multiple serious chronic skin
diseases. The Company plans to participate in upcoming dermatology conferences,
including as a sponsor in this week s Symposium on Hidradenitis Suppurativa
Advances to be held November 4-5, 2017, in Detroit, MI.
Brilacidin s potential application in dermatology to provide improved treatment options for people in need is discussed below.
From a scientific perspective, defensins which Brilacidin was designed to
mimic play an important and multifunctional role in regulating the skin
micro-environment. The increased susceptibility of people with Atopic Dermatitis
(Eczema) to S. aureus infections, significantly complicating this skin condition
and against which Brilacidin has been shown to have potent efficacy, is thought
to be influenced by the impaired expression of Host Defense Proteins (HDPs). Up
to a combined 50 million people, in the U.S. and major European markets, are
affected by Eczema. Brilacidin also exhibits strong anti-inflammatory effects on
key effector cells involved in the etiology of Hidradenitis Suppurativa (HS), a
burdensome skin disease affecting 1 to 4 percent of the world s population, and
for which there currently is only one approved marketed treatment (Humira).
Brilacidin s antimicrobial and wound healing properties might similarly benefit
HS sufferers. Pre-clinical lab work also indicates impressive Minimum Inhibitory
Concentration (MIC) values when Brilacidin was tested against Propionibacterium
spp. a type of bacteria expressed in Acne compared to other antibiotics, such as
Erythromycin, Clindamycin, Minocycline, Doxycycline and Metronidazole.
One key aspect of Brilacidin s Mechanism of Action, inhibiting Phosphodiesterase
4 (PDE4), might also contribute to its therapeutic potential in treating skin
diseases.
Linked below is additional information, published on the Company s website, elaborating on Brilacidin s treatment potential in various dermatological conditions.
Brilacidin s Potential Application in Dermatology http://www.ipharminc.com/new-blog/2017/6/5/br...ermatology The Clinical Need and Market Opportunity in Atopic Dermatitis http://www.ipharminc.com/new-blog/2017/6/21/t...dermatitis Toward Developing Newer Treatments for Hidradenitis Suppurativa http://www.ipharminc.com/new-blog/2017/5/30/h...ne-inversa
About Prurisol
Inc. (OTCQB:IPIX) ( the Company ), a clinical stage biopharmaceutical company,
is pleased to report continued developments in its dermatology franchise.
The Company s randomized, placebo-controlled Phase 2b clinical trial of Prurisol
for chronic, moderate-to-severe plaque psoriasis (see NCT02949388), enrolling a
total of 199 patients, remains on-track for completion in December. Separately,
building upon promising results seen to date demonstrating its
anti-inflammatory, anti-infective and immunomodulatory properties, the Company
is looking to expand Brilacidin into treating multiple serious chronic skin
diseases. The Company plans to participate in upcoming dermatology conferences,
including as a sponsor in this week s Symposium on Hidradenitis Suppurativa
Advances to be held November 4-5, 2017, in Detroit, MI.
Brilacidin s potential application in dermatology to provide improved treatment options for people in need is discussed below.
From a scientific perspective, defensins which Brilacidin was designed to
mimic play an important and multifunctional role in regulating the skin
micro-environment. The increased susceptibility of people with Atopic Dermatitis
(Eczema) to S. aureus infections, significantly complicating this skin condition
and against which Brilacidin has been shown to have potent efficacy, is thought
to be influenced by the impaired expression of Host Defense Proteins (HDPs). Up
to a combined 50 million people, in the U.S. and major European markets, are
affected by Eczema. Brilacidin also exhibits strong anti-inflammatory effects on
key effector cells involved in the etiology of Hidradenitis Suppurativa (HS), a
burdensome skin disease affecting 1 to 4 percent of the world s population, and
for which there currently is only one approved marketed treatment (Humira).
Brilacidin s antimicrobial and wound healing properties might similarly benefit
HS sufferers. Pre-clinical lab work also indicates impressive Minimum Inhibitory
Concentration (MIC) values when Brilacidin was tested against Propionibacterium
spp. a type of bacteria expressed in Acne compared to other antibiotics, such as
Erythromycin, Clindamycin, Minocycline, Doxycycline and Metronidazole.
One key aspect of Brilacidin s Mechanism of Action, inhibiting Phosphodiesterase
4 (PDE4), might also contribute to its therapeutic potential in treating skin
diseases.
Linked below is additional information, published on the Company s website, elaborating on Brilacidin s treatment potential in various dermatological conditions.
Brilacidin s Potential Application in Dermatology http://www.ipharminc.com/new-blog/2017/6/5/br...ermatology The Clinical Need and Market Opportunity in Atopic Dermatitis http://www.ipharminc.com/new-blog/2017/6/21/t...dermatitis Toward Developing Newer Treatments for Hidradenitis Suppurativa http://www.ipharminc.com/new-blog/2017/5/30/h...ne-inversa
About Prurisol
(7)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼